MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry ™ (tralokinumab-ldrm) for the treatment of moderate-to-severe atopic ...

Adbry是LEO Pharma在美国上市的首个生物制剂，预计将于2022年2月在药店出售。 tralokinumab在美国以外的商品名是Adtralza ® ，目前已在欧盟、英国、加拿大和阿联酋获批。 丹麦巴勒鲁普--(BUSINESS WIRE)--(美国商业资讯)--皮肤医学领域的全球领导者LEO Pharma A/S 今天宣布 ...

If you have atopic dermatitis, a skin condition commonly known as eczema, prescription creams or other topical medicines and moisturizers are usually enough to manage it. However, if your eczema is ...

The MarketWatch News Department was not involved in the creation of this content. LEO Pharma Presents Final Results of ECZTEND Long-Term Adbry(R) Trial (tralokinumab-ldrm) in Patients with Moderate-to ...

The new single-dose autoinjector is available in a 300mg/2mL dosage strength and is intended for use in adults only. The Food and Drug Administration (FDA) has approved a new single-dose autoinjector ...

The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD. The Food and Drug Administration ...